Literature DB >> 14575807

Probucol restores the defective leukocyte-endothelial interaction in experimental diabetes.

Renata C O Zanardo1, José W M C Cruz, Luis L Martinez, Maria Ap de Oliveira, Zuleica B Fortes.   

Abstract

Defective leukocyte-endothelial interactions have been observed in experimental type 1 diabetes. One of the mechanisms involved in the late complications of diabetes mellitus is the formation of free radicals species. Antioxidant treatment has been demonstrated to have beneficial effects on the complications observed in this pathology. Using intravital microscopy to visualize venules of the internal spermatic fascia, we demonstrated that the defective leukocyte-endothelial interactions in alloxan-induced diabetic rats could be corrected by probucol treatment. The defects were quantitated by the number of leukocytes rolling along the venular endothelium, sticking to the venular wall after topical application of zymosan-activated plasma (10%-0.1 ml) or leukotriene B4 (1 microM/0.1 ml) and migrated after the application of a local irritant stimulus (carrageenan, 100 microg/0.1 ml). Leukocyte counts, erythrocyte velocity and venular shear rate, unaltered in diabetic rats, were not modified by this treatment. Reactive oxygen species formation by endothelial cells increased in diabetic preparations, and the reduced expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and P-selectin in cross-sections of the whole testis of the animals, were both restored by the antioxidant agent. Therefore, antioxidant treatment improves leukocyte-endothelial interaction in diabetic rats at least in part by restoring the expression of adhesion molecules in venules of diabetic rats.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575807     DOI: 10.1016/j.ejphar.2003.08.043

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Impact of diabetes against the future risk of developing gout.

Authors:  García Rodríguez; Lucia Cea Soriano; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2010-06-22       Impact factor: 19.103

3.  Probucol attenuates overt pain-like behavior and carrageenan-induced inflammatory hyperalgesia and leukocyte recruitment by inhibiting NF-кB activation and cytokine production without antioxidant effects.

Authors:  Amanda Z Zucoloto; Marília F Manchope; Larrisa Staurengo-Ferrari; José C Alves-Filho; Thiago M Cunha; Maísa M Antunes; Gustavo B Menezes; Fernando Q Cunha; Rubia Casagrande; Waldiceu A Verri
Journal:  Inflamm Res       Date:  2017-04-06       Impact factor: 4.575

4.  Effect of probucol on insulin resistance in patients with non-diabetic chronic kidney disease.

Authors:  Rui Wang; Ri-Bao Wei; Yue Yang; Na Wang; Meng-Jie Huang; Cui-Ming Cao; Zi-Cheng Wang; Guang-Yan Cai; Xiang-Mei Chen
Journal:  J Geriatr Cardiol       Date:  2015-09       Impact factor: 3.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.